3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
12
Unknown
5
Recruiting
5
Not yet recruiting
2
Withdrawn
1
Terminated
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
78
Prostatic Neoplasms
56
Breast Neoplasms
50
Lung Neoplasms
31
Neoplasms
20
Neoplasm Metastasis
18
Stomach Neoplasms
14
Head and Neck Neoplasms
13
Squamous Cell Carcinoma of Head and Neck
12
Recurrence
7
Pancreatic Neoplasms
7
Ovarian Neoplasms
7
Adenocarcinoma of Lung
7
Sarcoma
6
Esophageal Neoplasms
6
Carcinoma, Transitional Cell
5
Carcinoma, Squamous Cell
5
Urinary Bladder Neoplasms
4
Colorectal Neoplasms
4
Carcinoma, Ovarian Epithelial
4
Triple Negative Breast Neoplasms
3
Advanced Non-Small Cell Lung Cancer
3
Adenocarcinoma, Bronchiolo-Alveolar
3
Solid Tumor
2
Small Cell Lung Carcinoma
2
Prostatic Neoplasms, Castration-Resistant
2
Inflammatory Breast Neoplasms
2
Hormone Refractory Prostate Cancer
2
HER2-positive Breast Cancer
2
Fallopian Tube Neoplasms
2
Interventions
Gemcitabine
8
Capecitabine
6
pembrolizumab
5
Carboplatin
5
Pemetrexed
3
Paclitaxel
3
Oxaliplatin
3
Irinotecan
3
regorafenib
2
osimertinib
2
Taxes
2
Sunitinib
2
Radiotherapy
2
Fluorouracil
2
Cisplatin
2
130-nm albumin-bound paclitaxel
2
trifluridine tipiracil drug combination
1
tislelizumab
1
tegafur-gimeracil-oteracil
1
technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran
1
sintilimab
1
seribantumab
1
selinexor
1
ruxolitinib
1
rubitecan
1
pralsetinib
1
palbociclib
1
olaparib
1
niraparib
1
linifanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Adenocarcinoma
×
Docetaxel
×
Clear all
NCT02387216
2021-10-12
SHERLOC
Elevation Oncology
Phase 2
Terminated
153 enrolled
19 charts